U.S. SECURITIES AND EXCHANGE COMMISSION
                             WASHINGTON, D.C. 20549

                                   FORM 12b-25
                           NOTIFICATION OF LATE FILING

[ ] Form 1O-K   [ ] Form 11-K   [X] Form 10-Q  [ ] Form N-SAR
For Period Ended: June 30, 2002

[ ] Transition Report on Form 10-K
[ ] Transition Report on Form 20-F
[ ] Transition Report on Form 11-K
[ ] Transition Report on Form 10-Q
[ ] Transition Report on Form N-SAR
For the Transition Period Ended:    ____________________________________

   Read Instruction Before Preparing Form.  Please Print or Type.

   Nothing in this form shall be construed to imply that the Commission has
   verified any information contained herein.

   If the notification relates to a portion of the filing checked above,
   identify the Item(s) to which the notification relates:

Part I - Registrant Information

         Full Name of Registrant: Disease Sciences, Inc.

         Former Name if Applicable:

         620 Herndon Parkway, Suite 360
         ---------------------------------------------------------
         Address of Principal Executive Office (Street and Number)

         Herndon, VA 20170
         -------------------------
         City, State and Zip Code

Part II - Rules 12b-25(b) and (c)

If the subject report could not be filed without unreasonable effort or expense
and the registrant seeks relief pursuant to Rule 12b-25(b) [Paragraph 23,047],
the following should be completed. (Check box, if appropriate)

[ ]   (a) The reasons described in reasonable detail in Part III of this form
      could not be eliminated without unreasonable effort or expense;

[X]   (b) The subject annual report, semi-annual report, transition report on
      Form 10-K, Form 20-F, 11-K or Form N-SAR, or portion thereof will be filed
      on or before the fifteenth calendar day following the prescribed due date;
      or the subject quarterly report or transition report on Form 10-Q, or
      portion thereof will be filed on or before the fifth calendar day
      following the prescribed due date; and

[ ]   (c) The accountant's statement or other exhibit required by Rule 12b-25(c)
      has been attached if applicable.

                                       1


Part III -  Narrative

State below in reasonable detail the reasons why the Form 1O-K, 20-F, 11-K,
10-Q, N-SAR, or the transition report or portion thereof could not be filed
within the prescribed time period.

      The Form 10-QSB could not be filed within the prescribed time because of
      additional time required by Registrant's management to provide certain
      information to be included in the Form 10-QSB.

Part IV - Other Information

         (1) Name and telephone number of person to contact in regard to this
notification:

         John K. Johnson          (703)           563-6565
         --------------------------------------------------------
         (Name)                (Area Code)    (Telephone Number)

         (2) Have all other periodic reports required under Section 13 or 15(d)
of the Securities Exchange Act of 1934 or Section 30 of the Investment Company
Act of 1940 during the preceding 12 months or for such shorter period that the
registrant was required to file such report(s) been filed? If the answer is no,
identify report(s).

                     [X] Yes          [ ] No

         (3) Is it anticipated that any significant change in results of
operations from the corresponding period for the last fiscal year will be
reflected by the earnings statements to be included in the subject report or
portion thereof?

                     [ ] Yes          [X] No

         If so: attach an explanation of the anticipated change, both
narratively and quantitatively, and, if appropriate, state the reasons why a
reasonable estimate of the results cannot be made.

                             Disease Sciences, Inc.
                  --------------------------------------------
                  (Name of Registrant as specified in charter)

has caused this notification to be signed on its behalf by the undersigned
thereunto duly authorized.


Date:    August 14, 2002                By: /s/ John K. Johnson
                                            ----------------------
                                            John K. Johnson
                                            Chief Financial Officer

                                       2